ABT logo Abbott Laboratories +
Abbott Laboratories
+

Abbott Laboratories (ABT) Business News

Track Abbott Laboratories in real time with a live news feed covering Abbott Laboratories stock news, official press releases, company announcements, and an archive of historical Abbott Laboratories news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:00 AM | Saturday | Jun 6, 2026 PRNewsWire

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

News Thumbnail
9:00 AM | Saturday | Jun 6, 2026 PRNewsWire

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

News Thumbnail
9:00 AM | Wednesday | May 27, 2026 PRNewsWire

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

News Thumbnail
7:01 AM | Wednesday | May 27, 2026 PRNewsWire

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

News Thumbnail
9:00 AM | Tuesday | May 26, 2026 PRNewsWire

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

News Thumbnail
9:00 AM | Tuesday | Apr 28, 2026 PRNewsWire

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

News Thumbnail
12:30 PM | Saturday | Apr 25, 2026 PRNewsWire

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

News Thumbnail
7:30 AM | Thursday | Apr 16, 2026 PRNewsWire

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

News Thumbnail
9:00 AM | Thursday | Apr 9, 2026 PRNewsWire

New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

News Thumbnail
9:00 AM | Monday | Mar 30, 2026 PRNewsWire

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

News Thumbnail
9:00 AM | Thursday | Mar 26, 2026 PRNewsWire

Abbott hosts conference call for first-quarter earnings

News Thumbnail

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

PRNewsWire

9:00 AM | Saturday | Jun 6, 2026

news photo
Loading...

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1 ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes.

Read full article redirect
9:00 AM | Saturday | Jun 6, 2026

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

PRNewsWire

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1 ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes.

Read full article arrow
News Thumbnail
9:00 AM | Saturday | Jun 6, 2026

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

PRNewsWire

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect early Ketone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in intervention Nearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1 ABBOTT PARK, Ill., June 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 27, 2026

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

PRNewsWire

First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre digital health ecosystem, allowing people to share glucose and ketone data with caregivers and healthcare providers Designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes.

Read full article arrow
News Thumbnail
7:01 AM | Wednesday | May 27, 2026

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

PRNewsWire

Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based options Recent publications support Cologuard-first strategy, demonstrating better outcomes for patients, providers, health systems, and payers ABBOTT PARK, Ill., May 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | May 26, 2026

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

PRNewsWire

Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show low anxiety and minimal psychological burden in real-world use ABBOTT PARK, Ill., May 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Apr 28, 2026

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

PRNewsWire

Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery The integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary disease to open clogged arteries The AI enabled software helps physicians size and position the stent more accurately, which can lead to better results for patients ABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.
S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software.

Read full article arrow
News Thumbnail
12:30 PM | Saturday | Apr 25, 2026

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

PRNewsWire

Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system ABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical... Read more

Read full article arrow
News Thumbnail
7:30 AM | Thursday | Apr 16, 2026

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

PRNewsWire

First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1 Abbott projects full-year 2026 adjusted diluted EPS of $5.
38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences ABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE: ABT) announced financial results for the first quarter ended March 31, 2026.

Read full article arrow
News Thumbnail
9:00 AM | Thursday | Apr 9, 2026

New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

PRNewsWire

With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health.

Read full article arrow
News Thumbnail
9:00 AM | Monday | Mar 30, 2026

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

PRNewsWire

Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisions Allows oncologists to order tests and view results directly in the clinical workflow ABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform.

Read full article arrow
News Thumbnail
9:00 AM | Thursday | Mar 26, 2026

Abbott hosts conference call for first-quarter earnings

PRNewsWire

ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.

Read full article arrow
News Thumbnail